Tolerability and pharmacodynamics of AXT 914 (45 or 60 mg/day) vs teriparatide in healthy postmenopausal women

Trial Profile

Tolerability and pharmacodynamics of AXT 914 (45 or 60 mg/day) vs teriparatide in healthy postmenopausal women

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs AXT 914; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top